Liminal Biosciences Inc engages in clinical-stage research and commercialization of fibrosis treatments. The company operates in two segments: Small molecule therapeutics and Plasma-derived therapeutics. The Small molecule segment develops and commercializes treatments for lung, liver, and kidney conditions. The Plasma-derived segment sells proteins and specialty plasma in addition to developing a plasma treatment product. Liminal Biosciences does business in Canada, the U.K., and the U.S., and nearly all of its revenue comes from the plasma-derived therapeutics segment.
Location: Canada, Laval
Employees: 201-500
Total raised: $105M
Founded date: 1994
Investors 3
| Date | Name | Website |
| - | Western Te... | westerntec... |
| - | Thomvest V... | thomvest.c... |
| 23.07.2021 | BDC | bdc.ca/ |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.08.2021 | - | $105M | - |
Mentions in press and media 2
| Date | Title | Description |
| 09.08.2021 | Liminal BioSciences : Announces Sale of Priority Review Voucher for USD105M | LAVAL, QC and CAMBRIDGE, England , Aug. 9, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that, its subsidiary Prometic Biotherapeutics Inc. ("P... |
| 05.05.2021 | LIMINAL BIOSCIENCES INC. Liminal BioSciences : Notice of Annual and Special Meeting of Shareholders and Management Information Circular | Notice of Annual and Special Meeting of Shareholders and Management Information Circular April 19, 2021 Table of Contents NOTICE OF 2021 ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS AND NOTICE OF AVAILABILITY OF MEETING MATERIALS 4 1 NOTICE O... |